• Mashup Score: 2

    Cardiovascular disease represents a major burden in people with type 2 diabetes, and the prevention of cardiovascular complications has become a main objective when treating at-risk people. Numerous cardiovascular outcome trials (CVOTs) were published in recent years that showed not only the cardiovascular safety, but also the efficacy, of new glucose-lowering therapies. However, almost all CVOTs used a placebo as comparator rather than an active agent, and there were no CVOTs that directly compared the cardiovascular effects between newer glucose-lowering agents—especially SGLT2 inhibitors versus GLP-1 receptor agonists.

    Tweet Tweets with this article
    • Linked Comment by André J Scheen: Pragmatic trials, a step forward to assess #cardiovascular efficacy of new #glucose-lowering agents https://t.co/sEkIbYq9Fe #T2D

  • Mashup Score: 3

    The life history theory assumes that all organisms are under selective pressure to harvest external resources and allocate them to maximise fitness: only organisms making the best use of energy obtain the greatest fitness benefits. The trade-off of energy spans four functions: maintenance, growth, reproduction, and defence against pathogens. The innovative antihyperglycaemic agents glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors decrease bodyweight and have the potential to counter low-grade inflammation.

    Tweet Tweets with this article
    • Personal View: #Glucose-lowering #drugs with #cardiovascular benefits as modifiers of critical elements of the human life history https://t.co/FdnQia5S6d #diabetes #obesity #SGLT2 inhibitors #GLP-1 receptor agonists

  • Mashup Score: 0

    Cardiovascular disease represents a major burden in people with type 2 diabetes, and the prevention of cardiovascular complications has become a main objective when treating at-risk people. Numerous cardiovascular outcome trials (CVOTs) were published in recent years that showed not only the cardiovascular safety, but also the efficacy, of new glucose-lowering therapies. However, almost all CVOTs used a placebo as comparator rather than an active agent, and there were no CVOTs that directly compared the cardiovascular effects between newer glucose-lowering agents—especially SGLT2 inhibitors versus GLP-1 receptor agonists.

    Tweet Tweets with this article
    • Linked Comment by André J Scheen: Pragmatic trials, a step forward to assess #cardiovascular efficacy of new #glucose-lowering agents https://t.co/sEkIbYq9Fe #T2D #CVD

  • Mashup Score: 1

    Cardiovascular disease represents a major burden in people with type 2 diabetes, and the prevention of cardiovascular complications has become a main objective when treating at-risk people. Numerous cardiovascular outcome trials (CVOTs) were published in recent years that showed not only the cardiovascular safety, but also the efficacy, of new glucose-lowering therapies. However, almost all CVOTs used a placebo as comparator rather than an active agent, and there were no CVOTs that directly compared the cardiovascular effects between newer glucose-lowering agents—especially SGLT2 inhibitors versus GLP-1 receptor agonists.

    Tweet Tweets with this article
    • Also read the Linked Comment: Pragmatic trials, a step forward to assess #cardiovascular efficacy of new #glucose-lowering agents https://t.co/sEkIbYq9Fe #T2D #CVD

  • Mashup Score: 0

    Cardiovascular disease represents a major burden in people with type 2 diabetes, and the prevention of cardiovascular complications has become a main objective when treating at-risk people. Numerous cardiovascular outcome trials (CVOTs) were published in recent years that showed not only the cardiovascular safety, but also the efficacy, of new glucose-lowering therapies. However, almost all CVOTs used a placebo as comparator rather than an active agent, and there were no CVOTs that directly compared the cardiovascular effects between newer glucose-lowering agents—especially SGLT2 inhibitors versus GLP-1 receptor agonists.

    Tweet Tweets with this article
    • André J Scheen comments on: Pragmatic trials, a step forward to assess #cardiovascular efficacy of new #glucose-lowering agents https://t.co/sEkIbYq9Fe #T2D #CVD

  • Mashup Score: 0

    Researchers will delve into the latest research in diabetes, obesity, reproductive health and other aspects of endocrinology during the Endocrine Society’s ENDO 2023 news conferences June 15-18.

    Tweet Tweets with this article
    • In addition, the #Hormones and #Technology News Conference explores how families of children with #diabetes could be using continuous glucose alarms to better protect against dangerous blood #glucose lows and highs: https://t.co/03ikXotiOq #CGM #ENDO2023 (3/3)

    • Our #Hormones and #Technology News Conference also covers a meta-analysis on closed-loop #insulin delivery systems designed to automate aspects of #diabetes management in children and teen: https://t.co/03ikXotiOq #ENDO2023 (2/3)

    • Our #Hormones and #Technology News Conference discusses a phase 1 study results for an orally administered robotic pill: https://t.co/03ikXotiOq #ENDO2023 (1/3)

  • Mashup Score: 1

    Physical activity performed in the afternoon could yield a greater reduction in HbA1c than physical activity during other times in the day, according to an analysis of data from the Look AHEAD trial published in Diabetes Care. “This is the first large-scale epidemiological study demonstrating that timing of unsupervised physical activity is associated with long-term improvement in blood

    Tweet Tweets with this article
    • #ICYMI: “While any amount of physical activity appears beneficial, the timing of the activity is linked to effects on blood #glucose management.” @BrighamResearch @JoslinDiabetes @ADA_DiabetesPro @ADA_Pubs https://t.co/3qEMd0kETx